- Home
- NERV vs MBRX Comparison
NERV vs MBRX Comparison
Compare NERV & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MBRX
- Stock Information
- Founded
- NERV 2007
- MBRX 2015
- Country
- NERV United States
- MBRX United States
- Employees
- NERV N/A
- MBRX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- MBRX Health Care
- Exchange
- NERV Nasdaq
- MBRX Nasdaq
- Market Cap
- NERV 12.6M
- MBRX 12.9M
- IPO Year
- NERV 2014
- MBRX 2016
- Fundamental
- Price
- NERV $1.77
- MBRX $0.31
- Analyst Decision
- NERV Hold
- MBRX Strong Buy
- Analyst Count
- NERV 1
- MBRX 3
- Target Price
- NERV $5.00
- MBRX $5.33
- AVG Volume (30 Days)
- NERV 12.2K
- MBRX 5.2M
- Earning Date
- NERV 08-05-2025
- MBRX 08-13-2025
- Dividend Yield
- NERV N/A
- MBRX N/A
- EPS Growth
- NERV N/A
- MBRX N/A
- EPS
- NERV 0.83
- MBRX N/A
- Revenue
- NERV N/A
- MBRX N/A
- Revenue This Year
- NERV N/A
- MBRX N/A
- Revenue Next Year
- NERV N/A
- MBRX N/A
- P/E Ratio
- NERV $2.18
- MBRX N/A
- Revenue Growth
- NERV N/A
- MBRX N/A
- 52 Week Low
- NERV $1.15
- MBRX $0.25
- 52 Week High
- NERV $3.50
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- NERV 57.10
- MBRX 24.39
- Support Level
- NERV $1.62
- MBRX $0.25
- Resistance Level
- NERV $1.83
- MBRX $0.42
- Average True Range (ATR)
- NERV 0.09
- MBRX 0.06
- MACD
- NERV -0.00
- MBRX -0.03
- Stochastic Oscillator
- NERV 64.29
- MBRX 13.07
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.